Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Intangibles for 10 consecutive years, with $174.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Intangibles fell 1.43% year-over-year to $174.0 million; the TTM figure through Mar 2026 stood at $174.0 million (down 1.43% YoY), while the FY2025 annual figure was $176.0 million, down 1.12% from the prior year.
• Intangibles eased to $174.0 million in Q1 2026 per RARE's latest filing, from $176.0 million in the prior quarter.
• Across five years, Intangibles topped out at $178.0 million in Q4 2024 and bottomed at $157.3 million in Q3 2023.
• Historically, Intangibles has averaged $166.7 million across 5 years, with a median of $165.0 million in 2024.
• Annual changes were most pronounced in 2022 — Intangibles grew 22.42% — and 2026, when it slipped 1.43%.
• Ultragenyx Pharmaceutical's Intangibles stood at $160.1 million in 2022, then climbed by 8.54% to $173.8 million in 2023, then grew by 2.43% to $178.0 million in 2024, then declined by 1.12% to $176.0 million in 2025, then fell by 1.14% to $174.0 million in 2026.
• Business Quant data shows RARE's Intangibles at $174.0 million in Q1 2026, $176.0 million in Q4 2025, and $172.9 million in Q3 2025.